Abstract
Archer Aviation Inc. will report fiscal results on August 10, 2026 Post-Mkt; our preview consolidates the company’s guidance and market estimates to frame revenue, profitability, and adjusted EPS expectations alongside key business drivers and analyst sentiment.
Market Forecast
Consensus points to a nascent revenue base this quarter with total revenue projected at 1.96 million US dollars, an estimated year-over-year increase of 881.86%; the company’s forecast implies EBIT of -245.29 million US dollars and EPS of -0.33, while consensus expects early-stage gross profit and net margins to remain negative or thin, with EBIT pressure persisting. Archer Aviation Inc.’s prior disclosures indicate limited commercial revenue recognition as its programs scale, with the main business centered on aerospace and defense prototyping and services; the most promising near-term driver remains initial services and program milestones, with projected revenue of 1.96 million US dollars and an 881.86% year-over-year rise.
Last Quarter Review
In the previous quarter, Archer Aviation Inc. reported revenue of 1.60 million US dollars, a gross profit margin of 18.75%, GAAP net loss attributable to common shareholders of -218.00 million US dollars with a quarter-on-quarter change of -15.25%, a net profit margin that remained negative, and adjusted EPS of -0.28 year-over-year decline of 64.71%. The quarter’s key operational highlight was better-than-expected top-line recognition relative to internal estimates. Main business activity was concentrated in aerospace and defense-related revenue of 1.60 million US dollars, with year-over-year growth effectively at an early baseline stage.
Current Quarter Outlook
Main business trajectory
Archer Aviation Inc.’s core revenue currently reflects early commercialization tied to aerospace and defense program activity, with this quarter’s revenue expected at 1.96 million US dollars. While the gross margin baseline was 18.75% last quarter, the mix this quarter could shift with milestone-based recognition and early service activity, leading to volatility in gross margin and net margin. EBIT is projected at -245.29 million US dollars and EPS at -0.33, indicating that operating expense intensity in certification, testing, and manufacturing scale-up remains the dominant driver of consolidated losses. Given the company’s stage, revenue sensitivity to program timing will be high and could lead to deviation from point estimates.
Most promising revenue lever
Management’s near-term growth axis is expected to be program milestone revenue and early services, modeled at 1.96 million US dollars this quarter with a year-over-year increase of 881.86%. This reflects the transition from negligible baseline revenue toward recognition linked to development progress and preparatory commercialization. As these revenues ramp from a small base, gross margin may oscillate around the high-teens level initially, but fixed-cost absorption will suppress operating margins. The durability of this lever hinges on the cadence of contracted milestones and the pace of pre-operational service deployments.
Key stock price sensitivities
Share performance this quarter is likely to be most sensitive to cash burn trajectory, visibility on certification and operational timelines, and any shifts in guidance that alter the path to scaled revenue. With EBIT modeled at -245.29 million US dollars, investors will scrutinize operating expense discipline and any commentary on capital requirements or financing strategy. Updates that demonstrate improved efficiency in R&D and manufacturing ramp, or that secure incremental program funding, could help narrow loss expectations and support sentiment; conversely, slippage in milestones or cost overruns would pressure the equity story.
Analyst Opinions
The prevailing analyst stance skews bullish, emphasizing the upside from the forecasted 881.86% year-over-year revenue growth from a nascent base and the potential for operational catalysts tied to program milestones this quarter; bears remain focused on heavy EBIT loss projections and funding needs, but they are the minority view. Well-followed institutions highlight the expected EPS of -0.33 and EBIT of -245.29 million US dollars as consistent with a scale-up phase, while targeting incremental validation milestones as share catalysts. The majority view contends that early revenue traction, even at 1.96 million US dollars, combined with clear progress updates on commercialization, can support a constructive near-term setup despite negative margins.Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments